智通财经APP获悉，百济神州(06160)盘中涨超4%，截至发稿，涨4.17%，报127.4港元，成交额1.24亿港元。
消息面上，近日，百济神州公布，公司自主研发的抗PD-1抗体药物百泽安(替雷利珠单抗注射液)、BTK抑制剂百悦泽(泽布替尼胶囊)分别新增三项适应症和一项适应症被纳入国家医保目录。此外，BTK抑制剂百悦泽新增一项适应症，绿叶制药合作引进产品百拓维新增一项适应症，安进公司授权引进产品凯洛斯成功续约。国家医保目录将自2025年1月1日起正式实施。国家医保目录将自2025年1月1日起正式实施。
公司指出，此次百泽安、百悦泽和合作引进产品百拓维新增适应症，以及凯洛斯成功续约国家医保目录，体现国家医疗保障局对临床价值高、价格合理的创新药品的支持和认可。纳入国家医保目录将有助于公司进一步提高该等产品在患者中的可负担性和可及性，也将有利于该等产品的市场推广和销售，对公司的长期经营发展具有一定积极作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.